SOUTH
SAN FRANCISCO, Calif., Jan. 12,
2025 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a precision medicine oncology company committed to
the discovery and development of targeted therapeutics, announced
its participation at the 43rd Annual J.P. Morgan Healthcare
Conference and provided 2025 corporate guidance and program
updates.
43rd Annual J.P. Morgan Healthcare Conference
Monday, January 13th,
2025, at 5:15 PM PT (8:15 PM ET)
- Presentation by Yujiro S. Hata,
Chief Executive Officer, IDEAYA Biosciences, followed by
analyst-hosted Q&A with Anupam
Rama, Managing Director, US SMID Biotechnology Equity
Research, J.P. Morgan
2025 Corporate Guidance to be Presented at the 43rd
Annual J.P. Morgan Healthcare Conference:
- Corporate financial guidance
- $1.2 billion of cash, cash
equivalents and marketable securities as of September 30, 2024, is anticipated to fund
operations into at least 2028
- Darovasertib, a potential first-in-class Phase 2/3 PKC
inhibitor program targeting Metastatic Uveal Melanoma (MUM) and
Uveal Melanoma (UM)
- Median progression free survival readout for potential Phase
2/3 registration-enabling trial of the darovasertib and crizotinib
combination in first-line (1L) patients with HLA-A2-negative MUM
targeted by year-end 2025, pending enrollment status and data
maturity. Enrollment has exceeded over 200 patients as of
January 6, 2025
- Phase 2 1L MUM median overall survival readout for the
darovasertib and crizotinib combination in approximately 38 1L MUM
patients targeted in 2025
- Targeting Phase 2 neoadjuvant UM clinical data update for
darovasertib in over 75 patients and a regulatory update in
2025
- Initiation of the Phase 3 registration-enabling trial for
darovasertib in neoadjuvant UM is planned for the first half of
2025
- IDE397, a potential first-in-class Phase 2 MAT2A Inhibitor
program targeting MTAP-deletion solid tumors
- Clinical program update(s) for Phase 1/2 study of IDE397 in
combination with Trodelvy® in MTAP-deletion urothelial
cancer (UC) in 2025
- Target to enable wholly owned IDE397 + IDE892 (IDEAYA PRMT5)
clinical combination in the second half of 2025 to target
MTAP-deletion non-small cell lung cancer (NSCLC)
- IDE849 (SHR-4849), a potential first-in-class Phase 1 DLL3
TOP1i ADC targeting Small Cell Lung Cancer (SCLC) and
Neuroendocrine Tumors (NETs)
- Clinical program update(s) targeted in 2025
- Updated IDE849 clinical program slides have been provided in
the JPM 2025 corporate presentation, including preclinical product
profile, CT-scan tumor size waterfall plot by RECIST 1.1, and SCLC
patient case study
- IDE275 (GSK959), a potential first-in-class Phase 1 Werner
Helicase program targeting MSI-high solid tumors
- Targeting presentation at a medical conference with GSK,
highlighting IDE275's differentiated potential best-in-class
profile, in the first half of 2025
- IDE161, a potential first-in-class Phase 1 PARG inhibitor
program targeting solid tumors
- Targeting Phase 1 expansion of IDE161 in combination with
KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in
MSI-high and MSS endometrial cancer in 2025
- Targeting clinical combination(s) of IDE161 with Topo-ADCs in
2025
- IDE705 (GSK101), a potential first-in-class Phase 1 Pol Theta
Helicase Inhibitor targeting homologous recombination deficiency
(HRD) solid tumors
- Targeting Phase 2 expansion in HRD solid tumors, enabling a
potential $10 million milestone
payment from GSK
- 3 IND-filings targeted in 2025, representing IDEAYA's
7th, 8th, and 9th potential
clinical stage precision medicine oncology program targeting solid
tumors
- IDE892, a potential best-in-class MTA-cooperative PRMT5
inhibitor, in mid-year 2025. Combination potential with IDE397
- IDE034, a potential first-in-class B7H3/PTK7 TOP1i bispecific
ADC, in the second half of 2025. Combination potential with
IDE161
- IDE251, a potential first-in-class KAT6/7 dual inhibitor
development candidate, in the second half of 2025. Combination
potential with multiple programs in IDEAYA's pipeline
IDEAYA's updated JPM 2025 corporate presentation reflecting its
2025 corporate guidance is available on its website under the
Investor Relations section: https://ir.ideayabio.com/.
A live audio webcast of the presentation and Q&A session
will be available under the "Investors/Events" section of the
IDEAYA website at https://ir.ideayabio.com/events and/or through
the conference host. A replay of the webcast will be accessible for
30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with drug discovery to select patient
populations most likely to benefit from its targeted
therapies. IDEAYA is applying its early research and drug
discovery capabilities to synthetic lethality – which represents an
emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to (i)
participation in and/or presentation at certain investor relations
events and (ii) 2025 corporate guidance regarding the extent to
which IDEAYA's existing cash, cash equivalents, and marketable
securities will fund its planned operations and (iii) program
updates regarding the potential timing of various activities.
IDEAYA undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of IDEAYA in general, see IDEAYA's
current and future filings with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 10-K filed on
February 20, 2024.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-participation-at-the-43rd-annual-jp-morgan-healthcare-conference-and-2025-corporate-guidance-302348559.html
SOURCE IDEAYA Biosciences, Inc.